| abstract |
The present invention relates to new peptides of the general formula (I) <B>R<1>-(B<1>)m-(B<2>)n-Tyr-(B<3a>)o(-B<3b>)p-Asnq-Asnr-Tyrs-Leut-B<4>-(Pro)u-Phe-Abu-B<5>-(B<6>)v-R<2>```(I)</B> wherein R<1> represents hydrogen or (C1-C8)-acyl, R<2> represents OH, O-(C1-C8)-alkyl, NH2 or Ala-Asp-Pro-OH, B<1> to B<6> represent, independent of one another, a basic amino acid, such as arginine, homoarginine, lysine, ornithine, 2,4-diaminobutyric acid or 2,3-diaminopropionic acid m,n,o,p,q,r,s,t,u,v represent, independent of one another, zero or 1, and their salts as well as pharmaceutical compositions characterized by containing a myotoxic phospholipase A2 (PLA2) or an other snake venom containing the common peptide sequence KKYKNNYLKPFCKK. The peptides and the pharmaceutical compositions can be used for the antagonisation of heparins, LMWH, pentasaccharide, danaparoid or other related anticoagulants. Reagent kits for in vitro analysis of blood or blood components are also described. |